Prolonged PEG-IFN and RBV Is Effective in Patients with HCV Genotype 1 and High Viral Load Who Achieved Virological Response Later than 24 Weeks | Zendy

Taisuke Ueda | Zendy; Hobyung Chung | Zendy; Masatoshi Kudo | Zendy; Emi Ishikawa | Zendy; Sousuke Hayaishi | Zendy; Chie Tatsumi | Zendy; Tatsuo Inoue | Zendy; Norihisa Yada | Zendy; Satoru Hagiwara | Zendy; Yasunori Minami | Zendy; Kazuomi Ueshima | Zendy

Open Access

Prolonged PEG-IFN and RBV Is Effective in Patients with HCV Genotype 1 and High Viral Load Who Achieved Virological Response Later than 24 Weeks

Author(s) -

Taisuke Ueda,

Hobyung Chung,

Masatoshi Kudo,

Emi Ishikawa,

Sousuke Hayaishi,

Chie Tatsumi,

Tatsuo Inoue,

Norihisa Yada,

Satoru Hagiwara,

Yasunori Minami,

Kazuomi Ueshima

Publication year - 2010

Publication title -

intervirology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.641

H-Index - 61

eISSN - 1423-0100

pISSN - 0300-5526

DOI - 10.1159/000252785

Subject(s) - ribavirin , medicine , viral load , pegylated interferon , gastroenterology , hepatitis c virus , genotype , combination therapy , immunology , interferon , virus , biology , biochemistry , gene

The extension of treatment duration has been proposed in late virological responders with hepatitis C virus (HCV) genotype 1 and high viral load. However, the effectiveness of extended treatment in patients whose serum HCV RNA become undetectable later than 24 weeks of treatment (ultra-late virological responder; ULVR) has not yet been determined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research